Chimerix's Strategic Progress and Upcoming Catalysts: A Promising Outlook for 2025
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
Express News | Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Here's Why Chimerix, Inc. (CMRX) Is Skyrocketing
Chimerix to Speak Today at The White House Cancer Moonshot Forum
Chimerix Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
JonesTrading Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $7
Chimerix Announces NDA Submission For Dordaviprone - Quick Facts
Chimerix Seeks Accelerated FDA Approval for Experimental Tumor Drug
Express News | Chimerix Inc - Enters Credit Facility of up to $30 Million With Svb
Chimerix Seeks FDA Approval for New Drug Targeting Deadly Brain Cancer
Express News | Chimerix Inc - Requests Priority Review for Nda
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients With Recurrent H3 K27M-Mutant Diffuse Glioma
Top-rated Smaller Defensive Stocks After Societe Generale Permabear Takes Contrarian View
Is Chimerix (NASDAQ:CMRX) In A Good Position To Invest In Growth?
H.C. Wainwright Maintains Chimerix(CMRX.US) With Buy Rating, Maintains Target Price $11
Express News | HC Wainwright & Co. Reiterates Buy on Chimerix, Maintains $11 Price Target
Chimerix Analyst Ratings
Edward White's Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA Plans